Irritable Bowel Syndrome Pipeline Analysis Report 2026

Report Coverage

The Irritable Bowel Syndrome Pipeline Analysis Report by Expert Market Research gives comprehensive insights into irritable bowel syndrome therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for irritable bowel syndrome. The irritable bowel syndrome report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The irritable bowel syndrome pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with irritable bowel syndrome treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to irritable bowel syndrome.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Irritable Bowel Syndrome Pipeline Outlook

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits, such as diarrhea, constipation, or both. It occurs due to abnormal gut-brain interactions, visceral hypersensitivity, and changes in gut motility and microbiota, often triggered by stress, infections, or dietary factors.

Irritable bowel syndrome treatment includes dietary changes, stress management, and medications such as antispasmodics, laxatives, and selective drugs based on symptoms, especially for IBS with constipation or diarrhea. In July 2022, the American Gastroenterological Association recommended linaclotide, plecanatide, and lubiprostone as pharmacological treatments in the irritable bowel syndrome with constipation (IBS-C) drug pipeline, improving fluid secretion and easing bowel movements.

Irritable Bowel Syndrome Epidemiology

According to Chaoping Li et al., 2024, irritable bowel syndrome (IBS) affects 7%-21% of the global population, with an estimated adult prevalence of 8.8%. In Asia, the rate is higher at 12.6%. According to Ashwin Porwal et al., 2024, IBS is more common in females and individuals under 50 years of age. The incidence rates vary in different countries, with factors such as dietary habits, lifestyle, and healthcare access. Only about 30% of those experiencing symptoms seek medical attention, indicating underdiagnosis and unmet treatment needs.

Irritable Bowel Syndrome – Pipeline Therapeutic Assessment

Irritable Bowel Syndrome Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II (accounts for 38%) covers a major share of the total irritable bowel syndrome clinical trials, highlighting strong mid-stage clinical activity. Phase III represents 29%, indicating significant progress toward regulatory approval. Phase I and phase IV each contribute 12.5%. This balanced development pipeline can accelerate innovative treatment availability, positively impacting market growth and patient outcomes.

Irritable Bowel Syndrome Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the irritable bowel syndrome pipeline analysis include small molecules, monoclonal antibodies, peptides, polymers, and gene therapies. The irritable bowel syndrome report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for irritable bowel syndrome. Serotonergic agents are emerging as promising candidates in the treatment pipeline for irritable bowel syndrome (IBS). For instance, LX1031, a tryptophan hydroxylase inhibitor, is under clinical evaluation. It targets serotonin production in the gastrointestinal tract to reduce abdominal pain and regulate bowel habits, offering a novel mechanism for managing non-constipation predominant IBS symptoms.

Irritable Bowel Syndrome Clinical Trials – Key Players

The EMR report for the irritable bowel syndrome pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed irritable bowel syndrome therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in irritable bowel syndrome clinical trials:

• Guangzhou Zhiyi Biotechnology Co., Ltd.
• TRYP Therapeutics
• CinPhloro Pharma, LLC
• NYU Langone Health
• AbbVie
• Ardelyx
• Tasly Pharmaceutical Group Co., Ltd.
• GlaxoSmithKline
• Urovant Sciences GmbH
• Shire Human Genetic Therapies, Inc.

Irritable Bowel Syndrome – Emerging Drugs Profile

Key Questions Answered in the Irritable Bowel Syndrome Pipeline Insight Report

• Which companies/institutions are leading the irritable bowel syndrome drug development?
• Which company is leading the irritable bowel syndrome pipeline development activities?
• What is the current irritable bowel syndrome commercial assessment?
• What are the opportunities and challenges present in the irritable bowel syndrome pipeline landscape?
• What is the efficacy and safety profile of irritable bowel syndrome pipeline drugs?
• Which company is conducting major trials for irritable bowel syndrome drugs?
• Which companies/institutions are involved in irritable bowel syndrome collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in irritable bowel syndrome?

Reasons To Buy This Report

The Irritable Bowel Syndrome Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for irritable bowel syndrome. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into irritable bowel syndrome collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Global Clinical Trials Market

Irritable Bowel Syndrome Treatment Market